Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 581-584

  Weber Hamann, Bettina ^a   Gilles, Maria ^a   Schilling, Claudia ^a   Onken, Vera ^a   Frankhauser, Pascal ^a   Kopf, Daniel ^a   Lederbogen, Florian ^a   Deuschle, Michael ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HYDROCORTISONE; INSULIN; MIRTAZAPINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; DRUG DERIVATIVE; MIANSERIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ENZYME IMMUNOASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HAMILTON SCALE; HOSPITAL PATIENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LETTER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; STATISTICAL ANALYSIS; AGED; COMPARATIVE STUDY; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIANSERIN; MIDDLE AGED;

EID: 58149123723     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31818582ef     Document Type: Letter

References (11)

1. Eaton WW, Anthony JC, Gallo J, et al. Natural history of DIS/DSM major depression: the Baltimore ECA follow-up. Arch Gen Psychiatry. 1997;5:993-999.
2. Kawakami N, Shimizu H, Takatsuka N, et al. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care. 1999;22:1071-1076.
3. Weber-Hamann B, Kopf D, Lederbogen F, et al. Activity of the hypothalamus-pituitary-adrenal system and oral glucose tolerance in depressed patients. Neuroendocrinology. 2005;81:200-204.
4. Weber-Hamann B, Gilles M, Lederbogen F, et al. Improved insulin sensitivity in 80 non- diabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry. 2006;67:1856-1861.
5. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry. 2006;67:421-424.
6. Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care. 2006;29:170.
7. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(suppl 1):S5-S20.
8. Stumvoll M, Yki-Järvinen H, Mitrakou A, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000;23:295-301.
9. Vogelzangs N, Suthers K, Ferrucci L, et al. Hypercortisolemic depression is associated with the metabolic syndrome in late-life Psychoneuroendocrinology. 2007;32:151-159.
10. Gorman JM. Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60(suppl 1):9-13.
11. Giordano M, Matsuda M, Sanders L, et al. Effects of angiotensin- converting enzyme inhibitors, Ca2+ channel antagonists, and -adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes. 1995;44:665-671.